New options for biologically targeted therapy of advanced non-small-cell lung cancer - sunitinib and sorasfenib

Abstract

Sunitinib and Sorafenib are multikinase inhibitors. The article sumarizes the current knowledge and experiences with use of two drugs in the treatment of advanced NSCLC.

Keywords

• biological therapy for NSCLC
• multikinase inhibitors
• sunitinib
• sorafenib